Arrowhead Research Corporation (ARWR) is a publicly traded Healthcare sector company. As of May 20, 2026, ARWR trades at $77.11 with a market cap of $10.42B and a P/E ratio of -35.25. ARWR moved +5.35% today. Year to date, ARWR is +7.95%; over the trailing twelve months it is +364.93%. Its 52-week range spans $9.57 to $82.26. Analyst consensus is strong buy with an average price target of $89.25. Rallies surfaces ARWR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arrowhead Shares Jump 6.95% on Surge in AI-Driven Cardiac Diagnostics Market Forecast: Arrowhead Pharmaceuticals shares rose 6.95% after Wall Street signaled strong interest in AI-driven cardiac diagnostics, as the global AI cardiology market is projected to expand from $2.78 billion this year to $14 billion by 2034. Hospitals eye machine-learning tools to cut diagnostic backlogs, driving institutional capital into Arrowhead’s sector.
| Metric | Value |
|---|---|
| Price | $77.11 |
| Market Cap | $10.42B |
| P/E Ratio | -35.25 |
| EPS | $-2.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $82.26 |
| 52-Week Low | $9.57 |
| Volume | 1.25M |
| Avg Volume | 0 |
| Revenue (TTM) | $622.01M |
| Net Income | $-271.86M |
| Gross Margin | 0.00% |
10 analysts cover ARWR: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.25.